Trial Profile
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Therapeutic Use
- 26 Sep 2023 Planned End Date changed from 17 May 2024 to 22 Sep 2024.
- 19 May 2023 Planned End Date changed from 30 Sep 2024 to 17 May 2024.
- 28 Oct 2021 Planned End Date changed from 29 Oct 2024 to 30 Sep 2024.